Hypera SA, a leading Brazilian pharmaceutical company, announced a drastic shift in its business strategy on October 21, 2024. The news caused its stock to plummet by 14%, closing at R$21.95. The company unveiled a plan to optimize working capital, aiming to boost operational cash generation by R$2.5 billion ($500 million) by 2028. Hypera projects […]